Abdulmecit Yavuz

Abdulmecit Yavuz

Auto-generated profile, based on publicly available information

Abdulmecit Yavuz

Department of Urology, Istinye University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in LUTS: Lower Urinary Tract Symptoms
Verified
Journal Article
Closed access
PDF file
AYAbdulmecit Yavuz
Abdulmecit Yavuz
MKMuhammet F. Kilinc
Muhammet F. Kilinc
MAMustafa Aydin
Mustafa Aydin
YOYilmaz Ofluoglu
Yilmaz Ofluoglu
GBGöksel Bayar
Göksel Bayar

23 December 2019 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
GBGöksel Bayar
Göksel Bayar
AYAbdulmecit Yavuz
Abdulmecit Yavuz
SCSedat Cakmak
Sedat Cakmak
YOYilmaz Ofluoglu
Yilmaz Ofluoglu
MKMuhammet Fatih Kilinc
Muhammet Fatih Kilinc
MAMustafa Aydın
Mustafa Aydın

6 August 2022 in Andrologia
Verified
Journal Article
Closed access
ÇYÇağlar Yıldırım
Çağlar Yıldırım
MSMehmet Yılmaz Salman
Mehmet Yılmaz Salman
AYAbdulmecit Yavuz
Abdulmecit Yavuz
GBGöksel Bayar
Göksel Bayar
We aimed to compare the efficacy of three tadalafil regimens for patients with type-2 diabetes mellitus (DM), at least one microvascular complication and erectile dysfunction (ED). Sixty patients attending our urology clinic with erectile problems and diagnosed with ED, having DM for at least 5 years, and at least one microvascular complication linked to DM were identified and randomly divided into three groups-Group I: used 5 mg tadalafil daily, Group II: used 20 mg tadalafil 2 h before sexual relations twice a week and Group III: used 5 mg tadalafil daily and an extra 15 mg tadalafil 2 h before sexual relations twice a week. After treatment, the median International Index of erectile function (IIEF-5) scores were significantly higher in Group III (15) compared to Groups I (8.5, p = 0.01) and II (9, p = 0.035). The groups were comparable in terms of the percentage of positive responses to the sexual encounter profile (SEP) 2 and the Global Assessment Questionnaires (GAQ)-1. However, the percentage of patients with positive responses to SEP-3 (20%, 40% and 75%, respectively) (p = 0.002) and GAQ-2 (20%, 45% and 75%, respectively) (p = 0.002) was significantly higher in Group III. Therefore, using a combination treatment (daily 5 mg + 15 mg when needed) to treat erectile function in patients with DM-related ED in the first stage may be more efficient with the same reliability and greater patient satisfaction.

3 September 2019 in Üroonkoloji Bülteni
Verified
Journal Article
Closed access
ADAyhan Dalkılıç
Ayhan Dalkılıç
GBGöksel Bayar
Göksel Bayar
MKMuhammet Fatih Kılınç
Muhammet Fatih Kılınç
AYAbdulmecit Yavuz
Abdulmecit Yavuz
OTOrhan Tanrıverdi
Orhan Tanrıverdi
KHKaya Horasanlı
Kaya Horasanlı

30 May 2025 in Endouroloji Bulteni
Verified
Journal Article
Open access
PDF file
AYAbdulmecit Yavuz
Abdulmecit Yavuz
SASerdar Arısan
Serdar Arısan
Objective: This study aimed to investigate the relationship between Fetuin-A glycoprotein, a known systemic and localized calcification inhibitor, and urinary system stone disease. Material and Methods: A total of 63 patients with urinary stone disease and 70 healthy controls were included. Serum Fetuin-A levels were measured using enzyme-linked immunosorbent assay, and various biochemical parameters were analyzed. Statistical comparisons were performed by using Pearson correlation to determine relationships, with significance set at p0.05). The mean age was 42.87 ± 11.0 years in the stone group and 41.6 ± 11.7 years in the control group (p=0.497). In the stone group, 65% were male and 35% female, while in the control group, 66% were male and 34% female, with no significant difference in gender distribution (p=0.831). Body mass index (BMI) was 25.3 ± 2.57 kg/m² in the stone group and 26.9 ± 3.08 kg/m² in the control group, also showing no significant difference (p=0.067). No correlations were found between serum Fetuin-A levels and other parameters such as age, BMI, or biochemical markers. Conclusion: Although some previous studies have suggested a relationship between Fetuin-A levels and urinary stone disease, this study found no significant association. Further research focusing on genetic polymorphisms of Fetuin-A may clarify its role in stone formation.

10 August 2026 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
CDCagri Dogan
Cagri Dogan
MŞMehmet Fatih Şahin
Mehmet Fatih Şahin
CYCenk Murat Yazıcı
Cenk Murat Yazıcı
ABAykut BAŞER
Aykut BAŞER
AYAbdülmecit Yavuz
Abdülmecit Yavuz
ACAlkan Cubuk
Alkan Cubuk